EXPEDITED REVIEW
Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein GraftsResults From the Randomized DELAYED RRISC Trial
Paul Vermeersch, MD1,
Pierfrancesco Agostoni, MD1,*,
Stefan Verheye, MD, PhD,
Paul Van den Heuvel, MD,
Carl Convens, MD,
Frank Van den Branden, MD,
Glenn Van Langenhove, MD, PhD DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators
Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Antwerp, Belgium.
Manuscript received April 2, 2007;
revised manuscript received May 18, 2007,
accepted May 21, 2007.
* Reprint requests and correspondence: Dr. Pierfrancesco Agostoni, Antwerp Cardiovascular Institute Middelheim, AZ Middelheim, Lindendreef 1, 2020 Antwerp, Belgium. (Email: agostonipf{at}gmail.com).
Objectives: We sought to provide long-term follow-up data of sirolimus-eluting stents (SES) versus bare-metal stents (BMS) in saphenous vein grafts (SVG) from the RRISC (Reduction of Restenosis In Saphenous vein grafts with Cypher) trial.
Background: We have previously shown that, in SVG, the use of SES reduces 6-month restenosis and repeated revascularization procedures versus the use of BMS. These data are consistent with trials in native coronary arteries. However, recently published long-term follow-up data of these trials have revealed an increased risk of adverse events (particularly very late stent thrombosis) after SES.
Methods: A total of 75 patients with 96 SVG lesions were randomized to SES versus BMS. All patients underwent clinical follow-up up to 3 years. Specific outcomes assessed in this secondary post-hoc analysis were all-cause mortality, myocardial infarction, and target vessel revascularization.
Results: Thirty-eight patients received 60 SES for 47 lesions, whereas 37 patients received 54 BMS for 49 lesions. At a median follow-up time of 32 months (interquartile range 26.5 to 36 months), 11 deaths (7 cardiac, of which 1 was caused by very late stent thrombosis and, 3 were sudden) occurred after SES (29% [95% confidence interval (CI) 17% to 45%]) versus 0 after BMS (0% [95% CI 0% to 9%]) with an absolute difference of 29% ([95% CI 14% to 45%], p < 0.001). The rates of myocardial infarction and target vessel revascularization were not different: 18% and 34% after SES, respectively, versus 5% and 38% after BMS, respectively (p = 0.15 and p = 0.74, respectively).
Conclusions: In this secondary post-hoc analysis, BMS were associated with lower long-term mortality than SES for SVG disease. Also, the 6-month reduction in repeated revascularization procedures with SES was lost at longer-term follow-up. (RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent; http://clinicaltrials.gov/ct/show/NCT00263263?order=1; NCT00263263
[ClinicalTrials.gov]
)
|
Abbreviations and Acronyms
| | BMS = bare-metal stent(s) | | CI = confidence interval | | MI = myocardial infarction | | SES = sirolimus-eluting stent(s) | | SVG = saphenous vein graft(s) | | TLR = target lesion revascularization | | TVR = target vessel revascularization |
|
Related Article
-
"Crying Fire in a Theater" or a "Confirmatory Sighting?"
- Stephen G. Ellis
J. Am. Coll. Cardiol. 2007 50: 268-269.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
D. T. Ko, H. Guo, H. C. Wijeysundera, M. I. Zia, V. Dzavik, M. W. A. Chu, S. E. Fremes, E. A. Cohen, and J. V. Tu
Long-Term Safety and Effectiveness of Drug-Eluting Stents for the Treatment of Saphenous Vein Grafts Disease: A Population-Based Study
J. Am. Coll. Cardiol. Intv.,
September 1, 2011;
4(9):
965 - 973.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Lee, S.-J. Park, D. E. Kandzari, A. J. Kirtane, W. F. Fearon, E. S. Brilakis, P. Vermeersch, Y.-H. Kim, R. Waksman, J. Mehilli, et al.
Saphenous Vein Graft Intervention
J. Am. Coll. Cardiol. Intv.,
August 1, 2011;
4(8):
831 - 843.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Ziada, A. Abdel-Latif, and M. E. Wiisanen
Reply
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
591 - 593.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Rozenman
Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Interventions
J. Am. Coll. Cardiol. Intv.,
May 1, 2011;
4(5):
590 - 591.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. W. Stone, S. Goldberg, C. O'Shaughnessy, M. Midei, R. M. Siegel, E. Cristea, G. Dangas, A. J. Lansky, and R. Mehran
5-Year Follow-Up of Polytetrafluoroethylene-Covered Stents Compared With Bare-Metal Stents in Aortocoronary Saphenous Vein Grafts: The Randomized BARRICADE (Barrier Approach to Restenosis: Restrict Intima to Curtail Adverse Events) Trial
J. Am. Coll. Cardiol. Intv.,
March 1, 2011;
4(3):
300 - 309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Brilakis, C. Lichtenwalter, A.-r. R. Abdel-karim, J. A. de Lemos, O. Obel, T. Addo, M. Roesle, D. Haagen, B. V. Rangan, B. Saeed, et al.
Continued Benefit From Paclitaxel-Eluting Compared With Bare-Metal Stent Implantation in Saphenous Vein Graft Lesions During Long-Term Follow-Up of the SOS (Stenting of Saphenous Vein Grafts) Trial
J. Am. Coll. Cardiol. Intv.,
February 1, 2011;
4(2):
176 - 182.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Wiisanen, A. Abdel-Latif, D. Mukherjee, and K. M. Ziada
Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Interventions: A Systematic Review and Meta-Analysis
J. Am. Coll. Cardiol. Intv.,
December 1, 2010;
3(12):
1262 - 1273.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-M. Paradis, P. Belisle, L. Joseph, O. F. Bertrand, R. DeLarochelliere, J.-P. Dery, E. Larose, J. Rodes-Cabau, and S. Rinfret
Drug-Eluting or Bare Metal Stents for the Treatment of Saphenous Vein Graft Disease: A Bayesian Meta-Analysis
Circ Cardiovasc Interv,
December 1, 2010;
3(6):
565 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Brilakis, T. Y. Wang, S. V. Rao, S. Banerjee, S. Goldman, K. Shunk, B. Kar, D. R. Holmes Jr, D. Dai, C. T. Chin, et al.
Frequency and Predictors of Drug-Eluting Stent Use in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions: A Report From the American College of Cardiology National Cardiovascular Data CathPCI Registry
J. Am. Coll. Cardiol. Intv.,
October 1, 2010;
3(10):
1068 - 1073.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Stolker, K. F. Kennedy, J. B. Lindsey, S. P. Marso, M. J. Pencina, D. E. Cutlip, L. Mauri, N. S. Kleiman, D. J. Cohen, and on behalf of the EVENT Investigators
Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry
Circ Cardiovasc Interv,
August 1, 2010;
3(4):
327 - 334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Brilakis, J. M. Lasala, D. A. Cox, P. B. Berger, T. S. Bowman, R. M. Starzyk, and K. D. Dawkins
Outcomes After Implantation of the TAXUS Paclitaxel-Eluting Stent in Saphenous Vein Graft Lesions: Results From the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) Program
J. Am. Coll. Cardiol. Intv.,
July 1, 2010;
3(7):
742 - 750.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Latib, L. Ferri, A. Ielasi, J. Cosgrave, C. Godino, E. Bonizzoni, E. Romagnoli, A. Chieffo, M. Valgimigli, C. Penzo, et al.
Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts
Circ Cardiovasc Interv,
June 1, 2010;
3(3):
249 - 256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Rodes-Cabau, O. F. Bertrand, E. Larose, J.-P. Dery, S. Rinfret, R. Bagur, G. Proulx, C. M. Nguyen, M. Cote, M.-C. Landcop, et al.
Comparison of Plaque Sealing With Paclitaxel-Eluting Stents Versus Medical Therapy for the Treatment of Moderate Nonsignificant Saphenous Vein Graft Lesions: The Moderate VEin Graft LEsion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) Pilot Trial
Circulation,
November 17, 2009;
120(20):
1978 - 1986.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R. Brodie, H. Wilson, T. Stuckey, M. Nussbaum, S. Laurent, B. Bradshaw, A. Humphrey, C. Metzger, J. Hermiller, F. Krainin, et al.
Outcomes With Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Intervention: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1105 - 1112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Douglas Jr
Are Our Patients Better Off With Drug-Eluting Stents in Saphenous Vein Grafts?
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1113 - 1115.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Carlsson, S. K. James, J. Lindback, F. Schersten, T. Nilsson, U. Stenestrand, B. Lagerqvist, and for the SCAAR (Swedish Coronary Angiography and An
Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On- and Off-Label Criteria
J. Am. Coll. Cardiol.,
April 21, 2009;
53(16):
1389 - 1398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Bittl
Drug-Eluting Stents for Saphenous Vein Graft Lesions: The Limits of Evidence
J. Am. Coll. Cardiol.,
March 17, 2009;
53(11):
929 - 930.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Brilakis, C. Lichtenwalter, J. A. de Lemos, M. Roesle, O. Obel, D. Haagen, B. Saeed, C. Gadiparthi, J. K. Bissett, R. Sachdeva, et al.
A Randomized Controlled Trial of a Paclitaxel-Eluting Stent Versus a Similar Bare-Metal Stent in Saphenous Vein Graft Lesions: The SOS (Stenting Of Saphenous Vein Grafts) Trial
J. Am. Coll. Cardiol.,
March 17, 2009;
53(11):
919 - 928.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R. Brodie, T. Stuckey, W. Downey, A. Humphrey, B. Bradshaw, C. Metzger, J. Hermiller, F. Krainin, S. Juk, B. Cheek, et al.
Outcomes and Complications With Off-Label Use of Drug-Eluting Stents: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
J. Am. Coll. Cardiol. Intv.,
August 1, 2008;
1(4):
405 - 414.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. T. Newsome, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Anesth. Analg.,
August 1, 2008;
107(2):
552 - 569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Bansal, R. Sachdeva, and J. L. Mehta
Percutaneous Intervention in Saphenous Vein Bypass Graft Disease: Case Against the Use of Drug-Eluting Stents
J. Am. Coll. Cardiol.,
March 4, 2008;
51(9):
970 - 971.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, F. Van den Branden, and G. Van Langenhove
Reply.
J. Am. Coll. Cardiol.,
March 4, 2008;
51(9):
971 - 972.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Increased Mortality with Sirolimus-Eluting Stents in Saphenous Vein Grafts?
Journal Watch Cardiology,
September 19, 2007;
2007(919):
1 - 1.
[Full Text]
|
 |
|

|
 |

|
 |
 
S. G. Ellis
"Crying Fire in a Theater" or a "Confirmatory Sighting?"
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
268 - 269.
[Full Text]
[PDF]
|
 |
|
|